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Lithium is used in the treatment of bipolar mood disorder. Reportedly, lithium can be neuroprotective in models of adult brain
ischemia. The purpose of this study was to evaluate the effects of lithium in a model of neonatal hypoxic–ischemic brain injury.
Nine-day-old male rats were subjected to unilateral hypoxia–ischemia (HI) and 2mmol/kg lithium chloride was injected i.p.
immediately after the insult. Additional lithium injections, 1mmol/kg, were administered at 24-h intervals. Pups were killed 6, 24
or 72h after HI. Lithium reduced the infarct volume from 24.7±2.9 to 13.8±3.3mm
3 (44.1%) and total tissue loss (degeneration
þ lack of growth) from 67.4±4.4 to 38.4±5.9mm
3 (43.1%) compared with vehicle at 72h after HI. Injury was reduced in the
cortex, hippocampus, thalamus and striatum. Lithium reduced the ischemia-induced dephosphorylation of glycogen synthase
kinase-3b and extracellular signal-regulated kinase, the activation of calpain and caspase-3, the mitochondrial release of
cytochrome c and apoptosis-inducing factor, as well as autophagy. We conclude that lithium could mitigate the brain injury after
HIbyinhibiting neuronalapoptosis.Thelithiumdosesusedwereinthesamerangeasthoseusedinbipolarpatients,suggesting
that lithium might be safely used for the avoidance of neonatal brain injury.
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Lithium is widely used in the treatment of bipolar disorder.
Recent studies have shown unexpected neuroprotective
effects in a variety of animal models of neurodegenerative
diseases.
1–3 The mechanisms underlying lithium-mediated
neuroprotectionarecomplexandmayincludeactivationofthe
phosphatidylinositol 3-kinase/Akt
4 pathway, activation of the
extracellular signal-regulated kinase (ERK) cell survival
pathway,
5 in addition to yet poorly understood pathways that
promote neuronal survival and proliferation.
6,7 Lithium treat-
ment may reduce caspase-3
8 and calpain
9 activation, as a
correlateofneuroprotection.Lithiumhasbeenshowntoinhibit
glycogen synthase kinase-3b (GSK-3b) activity through direct
or indirect mechanisms.
4,10 GSK-3b is generally considered
to have a proapoptotic role in thus for that its inhibition confers
cytoprotection.
11 Taken together, these ﬁndings provide a
strong rationale for the exploration of lithium as a potential
treatment of neurodegenerative diseases.
12
Lithium has a potent neuroprotective effect in adult brain
ischemia-reperfusion injury.
3,8 However, no information is
available on possible effects of lithium in neonatal brain injury.
At difference with neurons contained in the adult brain,
neurons from newborn rodents have a high propensity to
undergo apoptotic cell death, presumably because they still
express high levels of caspases.
13,14 Given the peculiar
importance of apoptotic cell death in the immature brain, one
may speculate that lithium could be particularly neuroprotec-
tive in this setting,
13,15 a hypothesis that we examined in this
study.
Perinatal asphyxia-induced brain injury is one of the most
common causes of morbidity and mortality, both in term and
preterm neonates, accounting for 23% of neonatal deaths
globally.
16 Survivors of perinatal asphyxia suffer long-term
neurological disability and impairment with major socio-
economic implications. Hypoxic–ischemic encephalopathy
(HIE) remains a major cause of acute perinatal brain injury,
ultimately leading to neurological dysfunctions such as
cerebral palsy, mental retardation and epilepsy. Although
many neuroprotective strategies have seemed promising in
animal models, most of them were not feasible or effective in
human newborns. There are very few randomized controlled
clinical trials that have shown improved outcomes for term
neonates. One method shown to have beneﬁcial effects is
hypothermia. Cooling the brains of term infants with moderate
HIE reduced the rate of disability if the treatment was initiated
within 6h.
17 Another, recently published trial showed that a
similar reduction of the rate of disability could be obtained by
repeatedinjectionsoflow-dosehumanerythropoietin.
18Thus,
there is an urgent, unmet need to develop new brain-
salvaging strategies that may be used either alone or in
combination with hypothermia and/or erythropoietin. In this
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www.nature.com/cddisstudy, we investigated the potential neuroprotective effects
of post-insult administration of lithium in neonatal rat hypoxia-
ischemia (HI) brain injury.
Results
Lithium reduced HI brain injury. At 72h after HI, the
histologically detectable brain injury encompassed areas in the
cortex, hippocampus, striatum and thalamus (Figure 1a).
Lithium treatment that was initiated shortly after HI was highly
efﬁcient in reducing brain injury. The infarct volume was
24.7±2.9mm
3 in the vehicle group and 13.8±3.3mm
3 in the
lithium-treated group, which corresponds to a 44.1% decrease
after lithium treatment (P¼0.016) (Figure 1b). The total tissue
loss was 67.4±4.4mm
3 in the vehicle group and
38.4±5.9mm
3 in the lithium group, corresponding to a 43.1%
decrease (P¼0.0003) (Figure 1c). Moreover, lithium treatment
reduced the pathological scores in all affected brain areas
including the cortex, hippocampus, striatum and thalamus
(Figure 1d).
Lithium prevents the acute dephosphorylation of
GSK-3b and ERK1/2 after HI. GSK-3b is normally
inhibited by Akt-mediated phosphorylation of the serine-9
residue. Phospho-GSK-3b-Ser9 (the inactive, protective form
of GSK-3b) was decreased 6h after HI in the injured,
ipsilateral hemisphere, and this dephosphorylation was
largely prevented by lithium treatment (Figures 2a and b).
Phospho-GSK-3b-Ser9 further decreased in both hemi-
spheres 24h after HI, and at this time point there was no
longer any difference between the treatment groups
(Figure 2a, lower panels). ERK1/2 activation (phosphory-
lation) decreased by approximately 80% in the ipsilateral hemi-
sphere 6h after HI compared with control or the contralateral
hemisphere (Figure 2c). Again, this dephosphorylation was
partially prevented by lithium treatment, such that the amount of
P-ERK1/2 almost doubled (and actually increased by 87%,
P¼0.0493, and 81.4%, P¼0.0487, for P-ERK1 and P-ERK2,
respectively) in the ipsilateral hemisphere (Figures 2d and e). As
i nt h ec a s eo fG S K - 3 b, both the ipsi- and the contralateral
hemispheres showed progressive loss of phosphorylated
ERK1/2 during recovery after HI, and at 24h after HI there
was only 10% P-ERK1/2 left. At this late time point, there were
no differences between the two hemispheres or between the two
treatment groups (Figures 2c–e).
Lithium inhibits calpain and caspase activation
after HI. We have previously shown that calpains and
caspase-3 are activated after HI in the immature brain.
13
Caspase-3 activation is a hallmark of apoptosis, whereas
Veh Veh
Li Li
*
Vehicle Lithium
80
60
40
20
0
I
n
f
a
r
c
t
 
v
o
l
u
m
e
 
(
m
m
3
)
***
150
100
50
0
T
i
s
s
u
e
 
l
o
s
s
 
(
m
m
3
)
Vehicle Lithium
Vehicle
Lithium **
* ** ***
P
a
t
h
o
l
o
g
i
c
a
l
 
s
c
o
r
e
4
3
2
1
0
Hip Str Cx Tha
Figure 1 Lithium treatment reduced HI brain injury. (a) Representative MAP2 stainings on the level of dorsal hippocampus (left panels) and striatum (right panels) 72h
after HI of vehicle- (upper panels) and lithium-treated mice (lower panels). (b) The infarct volume was reduced by 44.1% in lithium-treated mice (n¼28) as compared with
vehicle-treated mice (n¼28). (c) The volume of total tissue loss was reduced by 43.1% after lithium treatment. (d) Neuropathological scores showed less injury in all the
observed brain regions after lithium treatment. *Po0.05, **Po0.01, ***Po0.001
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Cell Death and Diseasecalpain activation may reﬂect both necrosis and apoptosis.
19
In this study, we determined the abundance of the 150kDa
fodrin breakdown product (FBDP), to indirectly assess
calpain activation.
19,20 FBDP-positive cells were increased
in the ipsilateral hemisphere after HI, and lithium treatment
decreased the number of FBDP-positive cells 6h after HI in
the cortex (Figure 3b) and 24h after HI in the hippocampus
(Figure 3c). The intact 240kDa fodrin was cleaved after HI,
revealing the calpain-generated 145/150kDa products and
the caspase-3-generated 120kDa product, all of which were
less abundant in the lithium-treated brains (Figure 3d).
Caspase-3 activity increased 30-fold 24h after HI, and this
increase was completely abolished after lithium treatment
(Figure 4a). The number of active caspase-3-positive cells
increased gradually during reperfusion after HI (Figure 4b),
and lithium treatment decreased the number of active
caspase-3-positive cells in the hippocampus 24h after HI
(Figure 4c). This was conﬁrmed also by immunoblotting,
showing that lithium treatment prevented processing of the
32kDa caspase-3 proform into the intermediate 29kDa and
active 17kDa fragments
19 (Figure 4d). Furthermore, the
endogenous caspase inhibitor, XIAP, was upregulated after
lithium treatment (Figure 4d).
Lithium inhibits mitochondrial release of apoptosis-
related proteins. Cytochrome c (Cyt c) is located in the
mitochondrial intermembrane space under normal
conditions, as indicated by a weak punctate cytoplasmic
immunostaining
21 (Figure 5a). In damaged areas, Cyt c was
released from mitochondria to the cytoplasm, producing an
intense neuronal, cytoplasmic staining (Figure 5a). Lithium
treatment decreased the number of Cyt c-positive cells in the
ipsilateral hemisphere 24h after HI in both cortex and
hippocampus (Figures 5b and c). Immunoblotting conﬁrmed
that the amount of of Cyt c that was associated with the
mitochondrial fractions was enhanced after lithium treatment.
This effect was most pronounced 24h after HI (Figure 5e), at
the same time when the reduction in caspase-3 activation
(shown above) is maximal. Apoptosis-inducing factor (AIF) is
another protein that is usually located in the intermembrane
space of mitochondria and that translocates to the nucleus
from injured cells (Figure 6a). Lithium treatment decreased
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Figure 2 Lithium prevented GSK-3b and ERK dephosphorylation. (a) Representative P-GSK-3b and GSK-3b imunoblots 6h (upper panel) and 24h (lower panel) after
HI. (b) Quantiﬁcation of P-GSK-3b 6h after HI showed that lithium prevented the loss in the ipsilateral hemisphere. (c) Representative P-ERK1/2 and ERK1/2 imunoblots 6h
(upperpanel)and24h(lowerpanel)afterHI.(dande)QuantiﬁcationofP-ERK1(ﬁgured)andP-Erk2(ﬁguree)6hafterHIshowedpartialpreventionofischemia-inducedloss
in the ipsilateral hemisphere after lithium treatment (n¼7 for HI 24h, n¼6 for all other groups). *Po0.05 compared with the vehicle group. Cont, control; CL, contralateral;
IL, ipsilateral
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Cell Death and Diseasethe number of AIF-positive nuclei 24h after HI in the
hippocampus (Figure 6b), and immunoblotting conﬁrmed
that lithium inhibited the AIF release from the mitochondrial
fraction (Figure 6c).
Lithium inhibits post-ischemic autophagy. LC3 immuno-
staining revealed intense, punctate staining in the cytoplasm
of neurons, particularly in injured areas (Figure 7a). The
number of LC3-positive cells was lower in lithium-treated
animals, an effect that was most pronounced 72h after HI
(Figures 7a and b). Immunoblots conﬁrmed increased
autophagy in the ipsilateral hemisphere 72h after HI, as
judged by increased levels of the 14kDa LC3-II, and this
biochemical sign of increased autophagy was reduced by
lithium treatment (Figure 7c).
Discussion
Lithium was discovered as a new element in 1817 by the
Swedish chemist Johan Arfwedson, and lithium has been
used for the treatment of mania from the 1870s onward. In
addition to the well-documented mood-stabilizing effects of
lithium in bipolar patients, recent in vitro and in vivo studies
have implicated lithium as a neuroprotective agent.
22 Putative
mechanisms include inhibition of GSK-3b, stimulation of heat
shock protein-70, inhibition of Ca
2þ inﬂux through NMDA
receptors, as well as activation of the ERK signaling path-
way.
23 However, these postulated mechanisms are based on
evidence generated in the adult nervous system. Cell death
cascades after ischemic insults are developmentally regu-
lated and apoptotic mechanisms seem to be particularly
important in the immature brain.
13,15 To the best of our
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Figure 3 Calpain activation after HI. (a) Representative FBDP stainings in the cortex (upper panel) and CA1 of the hippocampus (lower panel). (b) Quantiﬁcation of
FBDP-positive cells in the cortex showed signiﬁcantly fewer cells after lithium treatment 6h after HI. (c) Quantiﬁcation of FBDP-positive cells in the hippocampus showed
signiﬁcantly fewer cells after lithium treatment 24h after HI (n¼6 for HI 6h, n¼8 for HI 24h). (d) A representative fodrin immunoblot of homogenates showing that the
240kDa fodrin was cleaved in the ipsilateral hemisphere, producing 150 and 120kDa breakdown products 24h after HI, and that lithium treatment prevented fodrin
breakdown. *Po0.05 compared with the vehicle group (n¼7 for HI 24h, n¼6 for all other groups). Cont, control; CL, contralateral; IL, ipsilateral
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Cell Death and Diseaseknowledge, there are no published studies showing neuro-
protective effects of lithium in a neonatal brain injury
paradigm.
GSK-3, originally identiﬁed as a regulator of glycogen
metabolism, is now known asa multifaceted enzyme affecting
a diverse range of biological functions, including gene
expression, cellular architecture and apoptosis. In particular,
GSK-3b is well known to have critical roles in oxidative stress-
induced neuronal cell death by enhancing the expression of
pro-apoptotic proteins and by inhibiting the activity of anti-
apoptotic proteins. Lithium inhibits GSK-3b activity by direct
binding to the magnesium-sensitive active site of the
enzyme
24 and also indirectly by inducing the phosphorylation
of GSK-3b-Ser9 by other kinases.
4,25 Emerging evidence
supports the idea that GSK-3b inhibition is involved in the
neuroprotective effects of lithium.
1,26,27
An earlier study showed that P-Akt and P-GSK-3b
immunoreactivity was lost in the immature brain after HI and
that IGF-I treatment increased P-Akt, prevented P-GSK-3b
downregulation and afforded neuroprotection.
28 GSK-3b is
inhibited by phosphorylation at Ser9 through Akt. GSK-3b
may induce caspase activation either through the intrinsic
pathway or through downregulation of heat shock proteins.
29
On the basis of these previous studies, we speculate that
lithium-induced suppression of GSK-3b may account for its
anti-apoptotic and cytoprotective effects. Similarly, activation
of ERK1/2 occurred early in neurons after HI in the neonatal
brain
30 and has been coupled to protective mechanisms,
26
including lithium-mediated neuroprotection.
5At this stage,it is
difﬁcult to assess the relative contribution of lithium effects on
GSK-3 and ERK1/2 with regard to neonatal neuroprotection.
Reduced fodrin breakdown indicates that calpain activity
was decreased after lithium treatment.
21 However, there is no
evidence that lithium inhibits calpain activity directly.
2 There-
fore, inhibition of fodrin breakdown by lithium is probably
secondary to the general cytoprotective action of lithium
and/or to caspase inhibition,
19 as there is crosstalk between
calpains and caspase-3.
19 Apoptotic cell death has a
prominent role in the evolution of HI brain injury in neonates.
13
Our results indicate that lithium treatment inhibited mitochon-
drial release of both Cyt c and AIF, and subsequent apoptotic
cell death. GSK-3b activation has been shown to be critical for
the mitochondrial release of both Cyt c and AIF,
31 supporting
the conjecture that lithium inhibits mitochondrial outer
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Figure4 Lithiumpreventedcaspase-3activationafterHI.(a)Caspase-3activity(DEVDcleavage)wasmeasured6and24hpost-HIinbothvehicle-(Veh)andlithium-(Li)
treated rats (n¼7 for HI 24h, n¼6 for all other groups). Caspase-3 activation was abolished 24h after HI by lithium treatment. (b) Representative immunostainings for
activated caspase-3 in CA of the hippocampus in normal control (Cont), and Veh- or Li-treated rats 24h after HI. (c) Quantiﬁcation of active caspase-3-positive cells in CA of
the hippocampus showed signiﬁcant reduction in the lithium-treated rats 24h after HI (n¼6 for HI 6h, n¼8 for HI 24h). (d) Representative caspase-3, XIAP and actin
immunoblots of normal control (Cont), contralateral (CL) and ipsilateral (IL) hemispheres 24h after HI. The 32kDa proform was cleaved, and produced 29 and 17kDa
fragments after HI (upper panel). XIAP immunoblotting showed lithium-induced upregulation in the ipsilateral hemisphere 24h after HI (middle panel). The lower panel (actin)
indicates equal protein loading (n¼7 for HI 24h, n¼6 for all other groups). *Po0.05, ***Po0.001 compared with the Veh-treated HI group
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Cell Death and Diseasemembrane permeabilization by virtue of its action on GSK-3b.
Other studies have found that lithium treatment increased the
expression of Bcl-2 or heat shock protein and reduced the
levels of the pro-apoptotic proteins p53 and Bax.
1,32 Similarly,
we found that lithium upregulated the expression of the
endogenous caspase inhibitor XIAP. Together, these data
suggest that lithium-mediated neuroprotection may involve
multiple anti-apoptotic mechanisms.
33
Autophagy, a lysosomal pathway for intracellular bulk
degradation of cytoplasmic macromolecules and organelles,
has a key role to maintain cellular homeostasis and survival.
In this study, we show that autophagy was induced in the
neonatal brain after HI, as indicated by LC3 immuno-
blotting.
13,34 However, it is still debated whether enhanced
autophagyisinvolvedincelldeath
35orwhetheritrepresentsa
rescue mechanism.
36 Indeed, it has been suggested that
autophagy can have either deleterious or protective effects,
depending on the speciﬁc cellular context and the stage of the
pathological process.
37 One in vitro study showed that lithium
could induce autophagy,
38 but our current ﬁndings rather
indicate that lithium prevented autophagy during late recovery
after HI. It remains elusive whether this is secondary to the
lithium-mediated tissue protection resulting in less cellular
damage and hence less intracellular debris to be processed
by autophagy, or whether lithium directly inhibits autophagy
and thereby contributes to tissue protection.
Lithium is used in the treatment of bipolar affective disorder
since decades and has been used extensively off-label for
several other neuropsychiatric disorders. However, it has not
been approved, nor even suggested for fetal or neonatal
neuroprotection. The doses used in this study are in the same
range as those used for adult humans,
39 and it is encouraging
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Cell Death and Diseasethat a single daily administration was sufﬁcient to confer
neuroprotection. On the basis of these data, we conclude that
a further preclinical exploration of lithium for the treatment or
prevention of neonatal brain damage is warranted.
Materials and Methods
hypoxia–ischemia. Postnatal day 9 (P9) male Wistar rat pups were
purchased from B&K Universal AB (Sollentuna, Sweden). The rats were
randomly assigned to either lithium chloride or vehicle (saline) treatment. Animals
wereanesthetizedwithisoﬂurane(5% forinduction,1.5–2.0%formaintenance)in a
mixture of nitrous oxide and oxygen (1:1), the duration of anesthesia was o5min.
The left common carotid artery was cut between double ligatures of prolene sutures
(6.0). After the surgical procedure, the wounds were inﬁltrated with lidocaine for
local analgesia. The pups were returned to their cages for 1h and then placed in a
chamber perfused with a humidiﬁed gas mixture (7.7% oxygen in nitrogen) for
50min at361C.Followinghypoxicexposure, thepupswerereturnedto theircages.
Control pups were injected either with lithium chloride or vehicle but were not
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Cell Death and Diseasesubjected to HI. All animal experimentation was approved by the Gothenburg
Committee of the Swedish Animal Welfare Agency (application no. 145–2008).
Lithium administration. Lithium chloride (Aldrich, St. Louis, MO, USA) was
dissolved in normal saline and injected at a dose of 2mmol/kg intraperitoneally
immediately after HI, followed by 1mmol/kg injections at 24-h intervals. Animals
surviving 6h or 24h after HI received one injection. Animals surviving 72h after HI
received three injections.
Immunohistochemistry. The animals were deeply anesthetized with
phenobarbital and perfusion-ﬁxed with 5% formaldehyde in 0.1M PBS, followed
by immersion ﬁxation in the same ﬁxative for 24h at 41C. After dehydration with
graded ethanol and xylene, the brains were parafﬁn embedded, serial cut in 5mm
coronal sections and mounted on glass slides. Every 100th section was stained for
MAP-2. On the hippocampus level, every 50th section was stained. The sections
were stained for the following cell death-related markers: AIF, active caspase-3,
Cytc,microtubule-associatedprotein1, lightchain3(LC3)andFBDP,asdescribed
earlier.
13 Sections were deparafﬁnized and rehydrated. Antigen retrieval was
performedbyheatingthesectionsin10mMboilingsodiumcitratebuffer(pH6.0)for
10min. Nonspeciﬁc binding was blocked for 30min with 4% goat or horse serum
(depending on the species used to raise the secondary antibody) in PBS. Rabbit
anti-active caspase-3 (1:100, BD Pharmingen, Stockholm, Sweden), anti-FBDP
(1:50), anti-LC3 (1:300, #2775, Cell Signaling, Danvers, MA, USA), goat anti-AIF
(1:100, 2mg/ml, sc-9416, Santa Cruz, Santa Cruz, CA, USA) or mouse anti-Cyt c
(1:500, BD Pharmingen) were incubated for 60min at room temperature, followed
by the appropriate, biotinylated goat anti-rabbit (1:150, for active caspase-3, FBDP
and LC3), biotinylated horse anti-goat (1:200, for AIF) or biotinglated horse anti-
mouse (1:150) secondary antibody for 60min at room temperature. Endogenous
peroxidase activity was blocked with 3% H2O2 for 5min. Visualization was
performed using Vectastain ABC Elite with 0.5mg/ml 3,30-diaminobenzidine
enhanced with 15mg/ml ammonium nickel sulfate, 2mg/ml b-D glucose, 0.4mg/ml
ammonium chloride and 0.01mg/ml b-glucose oxidase (all from Sigma, Stockholm,
Sweden). The numbers of positive cells were counted on every 50th section in the
cortex and the whole cornu ammonis (CA) of hippocampus and at least six sections
werecounted.Thepositivecellsinthecortexwerecountedintheborderzoneandthree
high magniﬁcation visual ﬁelds (0.196mm
2) were counted in each section. The positive
cells in the CA were counted using unbiased stereological counting techniques
(StereoInvestigator, MicroBrightField Inc., Magdeburg, Germany). The cell density was
calculated from the sum of all cells counted divided by the counting volume.
Injury evaluation. Brain injury 72h after HI was evaluated using infarct
volume, total tissue loss and neuropathological scoring. The MAP2-positive
and -negative areas in each section were measured using Micro Image (Olympus,
Tokyo, Japan). The infarct volume was calculated from the MAP2-negative areas
according to Cavalieri principle, using the following formula: V¼
P
A   P   T,
where V¼ total volume,
P
A ¼ sum of area measurement, P ¼ the inverse of
the sampling fraction and T ¼ the section thickness. The total tissue loss was
calculated as the MAP2-positive volume in the contralateral hemisphere minus the
MAP2-positive volume in the ipsilateral hemisphere. The neuropathological score
for the cortex, hippocampus, striatum and thalamus was assessed as described
previously.
13 Brieﬂy, serial sections from each brain were stained for MAP2 and
scored by an observer blinded to the treatment of the animals. The cortical injury
was graded from 0 to 4, 0 being no observable injury and 4 indicating conﬂuent
infraction encompassing most of the cerebral cortex. The damage in the
hippocampus, striatum and thalamus was assessed both with respect to
hypotrophy (0–3) and observable cell injury/infarction (0–3) resulting in a
neuropathological score for each brain region (0–6).
Western blotting. Animals were killed by decapitation 6, 24 or 72h after HI.
Control animals were killed at the same time as HI pups after injection. The brains
were rapidly dissected out on a bed of ice. The parietal cortex (including the
hippocampus)wasdissectedoutfromeachhemisphereandice-coldisolationbuffer
was added (15mM Tris-HCl, pH 7.6, 320mM sucrose, 1mM DTT, 1mM MgCl2,
3mM EDTA-K, 0.5% protease inhibitor cocktail (P8340; Sigma), 1% phosphatase
inhibitor cocktail 1 (P2850, Sigma), 1% phosphatase inhibitor cocktail 2 (P5726,
Sigma) and 2.5mM cyclosporin A). Homogenization was performed gently by hand
in a 2ml glass–glass homogenizer (Merck Euro Lab, Dorset, England) using,
sequentially, two different pestles with a total clearance of 0.12mm and 0.05mm,
respectively (10 strokes each). The homogenates were centrifuged at 800 g for
10min at 41C. The pellets were washed in homogenizing buffer and re-centrifuged
at 800 g for 15min at 41C, producing a crude nuclear pellet (P1). The
supernatant from the ﬁrst centrifugation was further centrifuged at 9200 g for
15min at 41C, producing a mitochondrial and synaptosomal fraction in the pellet
(P2)and a crudecytosolicfraction in the supernatant (S2). Thepellet fractionswere
washed in homogenizing buffer and centrifuged at 9200 g for 15min. The protein
concentrations were determined according to Whitaker and Granum,
40 adapted for
microplates. Samples of 65ml were mixed with 25ml NuPAGE LDS 4   sample
buffer and 10ml reducing agent and heated (701C) for 10min. Individual samples
were run on 4–12% NuPAGE Bis-Tris gels (Novex, San Diego, CA, USA) and
transferred to reinforced nitrocellulose membranes. After blocking with 30mM
Tris-HCl (pH 7.5), 100mM NaCl and 0.1% Tween 20 containing 5% fat-free milk
powder for 1h at room temperature, the membranes were incubated with primary
antibodies: goat anti-AIF (sc-9416, 0.2mg/ml, Santa Cruz), rabit anti-caspase-3
(H-277, 1:1000, Santa Cruz), mouse anti-Cyt c (1:500, clone 7H8.2C12,
Pharmingen,SanDiego,CA,USA),rabbitanti-actin(1:200,A2066,Sigma),mouse
anti-fodrin (0.2mg/ml, clone AA6, BIOMOL, Plymouth Meeting, PA, USA), anti-
OxPhosComplexI 39kDa subunit(0.5mg/ml,p39,clone20C11,MolecularProbes,
Eugene,OR,USA), mouseanti-XIAP(clone28,1:250,BDBioscience,Stockholm,
Sweden), rabbit anti-LC3 (1:1000, Cell Signaling, #2775), mouse anti-GSK-3b
(1:1000, sc-81462, Santa Cruz), rabbit anti-phospho-GSK-3b (Ser9) (1:1000,
#9323,Cell Signaling), rabbit anti-ERK1/2(1mg/ml,AB3053,Chemicon, Temecula,
CA, USA) and rabbit anti-phospho-ERK (Thr202/Tyr204) (1:1000, #9101, Cell
Signaling), at room temperature for 60min. After washing, the membranes were
incubated with a peroxidase-labeled secondary antibody for 30min at room
temperature(goatanti-rabbit,1:2000,horseanti-goat,1:2000orhorseanti-mouse
1:4000). Immunoreactive species were visualized using the Super Signal West
Dura substrate (Pierce, Rockford, IL, USA) and a LAS 3000 cooled CCD camera
(Fujiﬁlm, Tokyo, Japan).
Caspase activity assay. The protein concentrations were determined as
above.Samplesofhomogenate(40ml)weremixedwith60mlofextractionbufferas
described earlier.
20 Cleavage of Ac-DEVD-AMC (for caspase-3/7 activity, Peptide
Institute, Osaka, Japan), was measured with an excitation wavelength of 380nm
and an emission wavelength of 460nm, and expressed as pmol AMC released
per mg protein and minute.
Statistics. All data were expressed as mean ± S.E.M. Student’s t-test was
used when comparing injury scores, tissue loss or the numbers of immunopositive
cellsbetweentwodifferentgroups.ANOVAwithFisher’sposthoctestwasusedwhen
comparing more than two groups. Signiﬁcance level was assigned at Po0.05.
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